How many institutions held LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value in Q1 2026?

29 institutional investors reported LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value for Q1 2026. Use the holders table for investor-level position and value details.

LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (LBRX)

Q: What does CUSIP 50180M108 represent in this 13F holders report?

CUSIP 50180M108 is the security identifier for LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value used to aggregate holder disclosures.

CUSIP: 50180M108

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.0001 par value
Shares outstanding: 29,134,041
Total 13F shares: 6,015,227
Share change: -187,921
Total reported value: $146,322,617
Price per share: $24.66
Number of holders: 29
Value change: -$3,995,808
Number of buys: 15
Number of sells: 13

Quarterly Holders Quick Answers

What is CUSIP 50180M108?
CUSIP 50180M108 identifies LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 50180M108:

Q1 2026 Q4 2025 Q3 2025

Top shareholders of LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Deep Track Capital, LP	13F 13D/G	Company	15% from 13D/G	3,352,804	$74,633,417	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	5.1% from 13D/G	2,238,934	$49,838,671	—	31 Dec 2025	13F 13D/G
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G	Company	8.7% from 13D/G	2,208,604	$49,163,525	—	31 Dec 2025	13F 13D/G
TCG Crossover Management, LLC	13F	Company	6%	1,745,015	$38,844,034	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F 13D/G	Company	4.9% from 13D/G	1,611,482	$35,871,589	—	31 Dec 2025	13F 13D/G
Commodore Capital LP	13F 13D/G	Company	5.5% from 13D/G	1,500,000	$33,390,000	—	31 Dec 2025	13F 13D/G
Trails Edge Capital Partners, LP	13F 13D/G	Company	5% from 13D/G	1,395,608	$31,066,234	—	31 Dec 2025	13F 13D/G
Logos Global Management LP	13F	Company	4.1%	1,200,000	$26,712,000	—	31 Dec 2025	13F
VANGUARD GROUP INC	13F	Company	3.8%	1,112,978	$24,774,891	—	31 Dec 2025	13F
Spruce Street Capital LP	13F	Company	3.5%	1,005,593	$22,384,500	—	31 Dec 2025	13F
BlackRock Portfolio Management LLC	13D/G	—	3.8%	961,158	$21,391,244	-$308,063	31 Dec 2025	13D/G
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	3.1%	896,806	$19,962,902	—	31 Dec 2025	13F
JENNISON ASSOCIATES LLC	13F	Company	2.8%	821,852	$18,294,425	—	31 Dec 2025	13F
Vivo Capital, LLC	13F	Company	2.7%	800,000	$17,808,000	—	31 Dec 2025	13F
Alyeska Investment Group, L.P.	13F	Company	2.3%	675,000	$15,025,500	—	31 Dec 2025	13F
Nantahala Capital Management, LLC	13F	Company	2.3%	675,000	$15,025,500	—	31 Dec 2025	13F
Deep Track Biotechnology Master Fund, Ltd.	3/4/5	10%+ Owner	— mixed-class rows	3,825,173 mixed-class rows	$10,000,003	+$10,000,004	06 Feb 2026	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	441,454	$9,829,858	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	1.4%	407,668	$9,074,690	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	1%	303,115	$6,747,340	—	31 Dec 2025	13F
Nan Fung Group Holdings Ltd	13F	Company	1%	300,000	$6,678,000	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.86%	250,030	$5,565,668	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.76%	221,865	$4,938,715	—	31 Dec 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	0.69%	200,000	$4,452,000	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.66%	193,544	$4,308,289	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.61%	177,616	$3,953,732	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.49%	143,966	$3,204,684	—	31 Dec 2025	13F
HighVista Strategies LLC	13F	Company	0.48%	140,107	$3,118,782	—	31 Dec 2025	13F
Integral Health Asset Management, LLC	13F	Company	0.34%	100,000	$2,226,000	—	31 Dec 2025	13F
Longbow Finance SA	13F	Company	0.28%	82,336	$1,832,799	—	31 Dec 2025	13F
Boxer Capital Management, LLC	13F	Company	0.24%	70,000	$1,558,200	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.17%	50,713	$1,128,872	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.15%	43,758	$974,053	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.14%	40,517	$901,908	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.11%	31,733	$706,377	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.1%	30,215	$672,586	—	31 Dec 2025	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.1%	30,000	$667,800	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.08%	24,641	$548,509	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.08%	22,966	$511,223	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.08%	22,303	$496,465	—	31 Dec 2025	13F
Focus Partners Wealth	13F	Company	0.07%	20,095	$447,315	—	31 Dec 2025	13F
NORGES BANK	13F	Company	0.07%	20,000	$445,200	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.07%	19,121	$425,633	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.06%	18,014	$400,992	—	31 Dec 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.06%	16,283	$362,454	—	31 Dec 2025	13F
DEUTSCHE BANK AG\	13F	Company	0.05%	13,298	$296,014	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.04%	12,720	$283,147	—	31 Dec 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.04%	12,445	$277,026	—	31 Dec 2025	13F
MetLife Investment Management, LLC	13F	Company	0.04%	11,104	$247,175	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.04%	11,074	$247,000	—	31 Dec 2025	13F

Institutional Holders of LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (LBRX) as of Q1 2026

As of 31 Mar 2026, LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value (LBRX) was held by 29 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 6,015,227 shares. The largest 10 holders included BlackRock, Inc., JPMORGAN CHASE & CO, VANGUARD CAPITAL MANAGEMENT LLC, JENNISON ASSOCIATES LLC, VANGUARD FIDUCIARY TRUST CO, UBS Group AG, VANGUARD PORTFOLIO MANAGEMENT LLC, Russell Investments Group, Ltd., Bank of New York Mellon Corp, and Calamos Advisors LLC. This page lists 29 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-38

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.